Navigation Links
deCODE Reinstated to Nasdaq Global Market
Date:6/26/2009

REYKJAVIK, Iceland, June 26 /PRNewswire-FirstCall/ -- deCODE genetics (Nasdaq: DCGN) today announced that it has received notice from the the Nasdaq Hearing and Listing Review Council that the listing of the company's common stock will be reinstated to the Nasdaq Global Market effective from the opening of trading on Monday, June 29. deCODE's common stock will continue to trade under the symbol DCGN.

The reinstatement follows the Listing Council's reversal of a decision in February by the Nasdaq Listing Qualifications Panel under which the listing of deCODE's common stock was transferred to the Nasdaq Capital Market.

About deCODE

deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases. Its lead therapeutic programs, which leverage the company's expertise in chemistry and structural biology, include DG041, an antiplatelet compound being developed for the prevention of arterial thrombosis; DG051 and DG031, compounds targeting the leukotriene pathway for the prevention of heart attack; and DG071 and a platform for other PDE4 modulators with therapeutic applications in Alzheimer's disease and other conditions. deCODE is a global leader in human genetics, and has identified key variations in the genome (SNPs) conferring increased risk of major public health challenges from cardiovascular disease to cancer. Based upon these discoveries deCODE has brought to market a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases. Through its CLIA-registered laboratory, deCODE offers deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of gl
'/>"/>

SOURCE deCODE genetics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
2. deCODE Study Shows Complex Interplay of the Human Biological Clock With Height, Weight and Disease
3. deCODE genetics Announces First Quarter 2009 Financial Results
4. deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2009 Financial Results
5. Nasdaq Stays Suspension of Trading in deCODE Stock
6. deCODE and Celera Partner to Expand use of deCODE Risk Markers for Heart Attack, Stroke and Diabetes
7. deCODE to Utilize Grace Period for Interest Payment on Senior Convertible Notes
8. deCODE genetics Announces Webcast of Conference Call to Discuss Full-year 2008 Financial Results
9. Multinational deCODE Study Identifies New Link Between Inflammation and Heart Attack
10. deCODE Announces Transfer of the Listing of its Common Stock from Nasdaq Global Market to Nasdaq Capital Market
11. deCODE Discovers First Genetic Variant Conferring Increased Risk of Essential Tremor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014  PAREXEL International Corporation (NASDAQ: ... be presenting at the Baird Healthcare Conference in New ... Chief Financial Officer, will be making a presentation on ... on Wednesday, Sept. 3, 2014. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:8/20/2014)... Canada (PRWEB) August 20, 2014 Not ... that E&L studies should be performed late in the ... is known. But current regulatory trends suggest that, like ... on the rise. In recent years, multiple drug sponsors ... packages or address specific questions during phase I/II. It’s ...
(Date:8/20/2014)... the health of your heart, researchers have discovered. , ... standard TENS machine like those designed to relieve labour ... small raised flap at the front of the ear ... stimulation changed the influence of the nervous system on ... drive failing hearts too hard. , Professor Jim Deuchars, ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... , , , ... the Sciences in Education over the Next Decade , WASHINGTON, Dec. ... continuously published magazine in the U.S., hosted The Decade-2 ... to promote the teaching of math and science to America,s students and was ...
... , , PROVIDENCE, R.I., Dec. 9 The ... disease (AD), which was conducted at 30 sites around the ... Neurology®. Lead author, Stephen P. Salloway, MD, MS, director ... professor of neurology and psychiatry at the Warren Alpert Medical ...
... , SAN DIEGO, Dec. 9 Sangart, Inc., a ... designed to enhance the perfusion and oxygenation of ischemic ... delivery, today announced that the European Commission (EC) has ... treatment of sickle cell disease. This designation provides ten ...
Cached Biology Technology:Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 2Science Education Experts Discuss Solutions for Global Competitiveness at Scientific American Forum 3Butler Hospital Neurologist Lead Author of Ground Breaking Bio-Engineered Treatment Study for Alzheimer's Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 2Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease 3
(Date:8/21/2014)... ignore, but they are the ultimate source of all ... increasingly dependent on algae, too, to suck up climate-warming ... the bottom of the ocean. Now, by using a ... evidence showing that viruses infecting those algae are driving ... all else stays essentially the same, and this has ...
(Date:8/21/2014)... the food intake, health and quality of life of ... projects at the University of Waterloo receiving close to ... Health Research (CIHR). , Professor Heather Keller, of ... a Schlegel research chair in nutrition and aging, will ... Canadians living in long-term care homes are poorly nourished. ...
(Date:8/21/2014)... is a key region in the global oceanic circulation. "On ... warm Atlantic water flows to the north into the Arctic ... and sea ice push their way out of the Arctic ... water cools here on its way to the north and ... in this manner drives the global band of oceanic currents ...
Breaking Biology News(10 mins):Viruses take down massive algal blooms, with big implications for climate 2Grants will fund landmark aging research at Waterloo 2Arctic sea ice influenced force of the Gulf Stream 2Arctic sea ice influenced force of the Gulf Stream 3
... cause poor lung development in children, making them more vulnerable ... in life, say researchers at the University of Pittsburgh Graduate ... Environmental Health. Their study, published online in Physiological Genomics ... in both mouse lungs and children ages 9 to 11. ...
... with the flu virus, we have investigated how the ... of the Experimental Mouse Genetics research group. In infection ... immune response is responsible for the fatal outcome of ... The findings have now been published in the scientific ...
... 2009 A material developed at the Hebrew University ... tissue) following surgery has led to approval by the ... for use in pediatric cardiac surgery patients. ... invention of novel, tailor-made, biodegradable polymers for the prevention ...
Cached Biology News:Changes in gene may stunt lung development in children 2The host makes all the difference 2Hebrew University professor's work leads to FDA approval for product 2
QPRT Immunogen: QPRT (NP_055113, 198 a.a. ~ 298 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Antibody Diluent for IHC 125 ml...
Quinolinate phosphoribosyltransferase...
JMJD2B Antibody...
Biology Products: